Advisors Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Advisors Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.44M	Sell	9,146 -3,054	-25%	-$713K	0.04%	554
2026 Q1	$2.79M	Sell	12,200 -194	-2%	-$43.5K	0.05%	496
2025 Q4	$2.64M	Buy	12,394 +1,785	+17%	+$369K	0.04%	513
2025 Q3	$2.11M	Buy	10,609 +137	+1%	+$25.6K	0.04%	584
2025 Q2	$1.81M	Buy	10,472 +1,282	+14%	+$209K	0.03%	593
2025 Q1	$1.43M	Buy	9,190 +949	+12%	+$136K	0.03%	654
2024 Q4	$1.13M	Buy	8,241 +3,499	+74%	+$460K	0.02%	713
2024 Q3	$708K	Buy	4,742 +894	+23%	+$121K	0.01%	824
2024 Q2	$525K	Buy	+3,848	New	+$524K	0.01%	879
2023 Q4	–	Sell	-5,519	Closed	-$517K	–	1405
2023 Q3	$517K	Sell	5,519 -98	-2%	-$9.17K	0.01%	895
2023 Q2	$501K	Sell	5,617 -270	-5%	-$23.5K	0.01%	930
2023 Q1	$631K	Sell	5,887 -254	-4%	-$29.1K	0.01%	883
2022 Q4	$750K	Sell	6,141 -9,675	-61%	-$1.12M	0.02%	842
2022 Q3	$1.63M	Sell	15,816 -933	-6%	-$88.5K	0.03%	566
2022 Q2	$1.56M	Sell	16,749 -22	-0.1%	-$2.07K	0.03%	599
2022 Q1	$1.97M	Buy	16,771 +520	+3%	+$60.2K	0.03%	590
2021 Q4	$2.19M	Buy	16,251 +1,443	+10%	+$215K	0.03%	571
2021 Q3	$2.36M	Sell	14,808 -212	-1%	-$29K	0.04%	544
2021 Q2	$1.98M	Buy	15,020 +1,240	+9%	+$165K	0.03%	604
2021 Q1	$1.78M	Buy	13,780 +5,267	+62%	+$800K	0.03%	634
2020 Q4	$1.42M	Buy	8,513 +3,916	+85%	+$648K	0.02%	678
2020 Q3	$709K	Buy	4,597 +560	+14%	+$80.5K	0.01%	809
2020 Q2	$597K	Buy	4,037 +2,693	+200%	+$370K	0.01%	848
2020 Q1	$151K	Buy	+1,344	New	+$175K	﹤0.01%	1160

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Advisors Asset Management's ASND Position: Q2 2026 in Review

Advisors Asset Management reduced its Ascendis Pharma A/S (ASND) stake by 25% in Q2 2026, selling an estimated $713K and leaving 9,146 shares worth $2.44M. The position accounts for 0.04% of the portfolio, ranked #554.

Advisors Asset Management first reported a position in ASND in Q1 2020 and has held it in 24 quarters since. The position peaked at $2.79M in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Advisors Asset Management held 9,146 shares of Ascendis Pharma A/S worth $2.44M as of Q2 2026.
Advisors Asset Management sold 3,054 Ascendis Pharma A/S shares in Q2 2026, an estimated $713K.
Ascendis Pharma A/S made up 0.04% of Advisors Asset Management's portfolio in Q2 2026, its #554 holding.
Advisors Asset Management first reported a position in Ascendis Pharma A/S in Q1 2020 and has held it in 24 quarters since.
Advisors Asset Management's Ascendis Pharma A/S position peaked at $2.79M in Q1 2026.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.